• DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Parasitic worms
      • Mycetoma
      • Dengue
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Evidence for impact
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi West and Central Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
      • Media workshops
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • Our story
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
  • DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Parasitic worms
      • Mycetoma
      • Dengue
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Evidence for impact
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi West and Central Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
      • Media workshops
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • Our story
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home

Press

Home

Press

DNDi’s media team welcomes inquiries from journalists, academia, and the general public. You can contact us at media@dndi.org. 

Would you like to receive our news and press releases in your inbox as soon as they are published? Please send us an email and we will add you to our media directory. 

filters

Type & Disease
Topic
Location
Date Range
Type & Disease

By Type

news type

By Disease

diseases

Topic

By Topic

topic type

Location

By Location

location-news

Date Range

By Year

date range filter – slider
1999 — 2026

Results

No results found. Please try using different filter option(s).

News
31 Mar 2026

DNDi is looking for a Board Treasurer to join its Board of Directors

Chemistry World logo, C and W letters in a light grey on a black background
In the media
26 Mar 2026

Boron plays a key role in new sleeping sickness drug

Chemistry World
Title copy on white and orange background, picture of Fr Robinson on the right hand
Videos
26 Mar 2026

Manufacturing medicines for NTDs, with Dr Stephen Robinson

Scientific articles
14 Jan 2026

(Un)intended consequences: a social sciences stocktake of a decade of Global Action Plan-inspired antimicrobial governance

The Lancet Microbe
Scientific articles
24 Mar 2026

The burden of eumycetoma in Africa: a neglected fungal disease

The Lancet Regional Health – Africa
Statements
23 Mar 2026

DNDi statement at the sixth meeting of the Intergovernmental Working Group (IGWG) on the WHO Pandemic Agreement

TV5Monde-logo
In the media
18 Mar 2026

RD Congo : Un nouveau traitement contre la maladie du sommeil

TV5Monde
NPR logo
News
16 Mar 2026

A new drug could be the beginning of the end for sleeping sickness

NPR
Science logo
News
16 Mar 2026

The Best Weapon Yet Against Sleeping Sickness

Science
Sci Dev Net logo
News
16 Mar 2026

Why sleeping sickness pill is raising hopes in Africa

SciDev.Net
El Periódico logo
In the media
15 Mar 2026

Tres pastillas en una dosis única, la bala de plata contra la enfermedad del sueño

El Periódico
In the media
14 Mar 2026

Africa’s one-dose cure brings sleeping sickness elimination within reach

The Independent
Nature logo
In the media
12 Mar 2026

Single-dose sleeping sickness drug set for approval

Nature
Sci Dev Net logo
In the media
12 Mar 2026

Faire des morsures de serpent une priorité de santé publique

SciDev.Net
Woman and Men in their house smiling
News
12 Mar 2026

2025 R&D programmes in review: Sleeping sickness

Woman in a field smiling
News
12 Mar 2026

2025 R&D programmes in review: Leishmaniasis

loading

Press Releases

Loading…
filter by
Press releases
Press Releases Translations
Press releases
4 Mar 2026

Pandemic preparedness: Novo Nordisk Foundation renews its support to DNDi and THSTI to continue the development of broad-spectrum antivirals

Acoziborole pill in hand
Press releases
27 Feb 2026

Acoziborole Winthrop, developed by DNDi and Sanofi, receives European Medicines Agency positive opinion as three-tablet, single-dose treatment for most common form of sleeping sickness

Press releases
10 Feb 2026

DNDi and Dubai Health launch Middle East partnership to advance research and training in neglected diseases

Press releases
27 Nov 2025

International seminar explores the development of treatments for dengue for populations not covered by vaccines

see ALL

In the Media

Loading…
Chemistry World logo, C and W letters in a light grey on a black background
In the media
26 Mar 2026

Boron plays a key role in new sleeping sickness drug

Chemistry World
TV5Monde-logo
In the media
18 Mar 2026

RD Congo : Un nouveau traitement contre la maladie du sommeil

TV5Monde
Sci Dev Net logo
News
16 Mar 2026

Why sleeping sickness pill is raising hopes in Africa

SciDev.Net
Science logo
News
16 Mar 2026

The Best Weapon Yet Against Sleeping Sickness

Science
see ALL

Connect and share

Follow us on social media to stay updated and help us share the stories of neglected patients.  

Linkedin Instagram X-twitter Facebook Youtube
EM PORTUGUÊS
EN ESPAÑOL
Linkedin-in Instagram Twitter Facebook-f Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films, and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International license